Saturday, July 11, 2026

pharma · Apnea of Prematurity · Safety and Pharmacokinetics

BELPHARMA

Belpharma is a pharma organization headquartered in LUXEMBOURG, LU. Primary therapeutic focus areas include Apnea of Prematurity, Safety and Pharmacokinetics. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s)

Luxembourg, LU HQ
2011 Founded
16 Employees
EMA registrant Type
Company details
Status
Public
HQ
Luxembourg, LU
Founded
2011
Employees
16
Programs
3
Drugs
2
Patents
0

Quick answer

Belpharma is a pharma organization headquartered in LUXEMBOURG, LU. Primary therapeutic focus areas include Apnea of Prematurity, Safety and Pharmacokinetics. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (2), phase 3 (1).

Company snapshot

BELPHARMA is an independent & privately owned pharmaceutical and biotech company. Our responsibility is to ensure continuity of access to patients & healthcare professionals to our portfolio of unique & targeted therapeutic solutions. Our operational focus is on the development of an international network of strategic alliances with reputable agents & on the operational management of commercial co

  • 3 active pipeline program(s) linked via ClinicalTrials.gov.
  • 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for BELPHARMA. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum signals

Momentum

Proprietary activity score for BELPHARMA.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 3 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d
Competitive landscape
Recent activity

Recent activity

Latest pipeline, patent, and corporate events for BELPHARMA.

  1. Clinical update

    NPC-11 for intravenous or oral administration. — Phase 3

  2. Clinical update

    NPC-22 — Phase 1

  3. Clinical update

    NPC-22 — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is BELPHARMA?

    Belpharma is a pharma organization headquartered in LUXEMBOURG, LU. Primary therapeutic focus areas include Apnea of Prematurity, Safety and Pharmacokinetics. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA

  • Is BELPHARMA publicly traded?

    BELPHARMA appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does BELPHARMA develop or market?

    We link 2 drug profile(s) where BELPHARMA is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/belpharma-s-a#company-drugs.

  • What are the latest developments for BELPHARMA?

    In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does BELPHARMA focus on?

    BELPHARMA focuses on Apnea of Prematurity, Safety and Pharmacokinetics based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
5